Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models. (Q38848501)

From Wikidata

Jump to navigation Jump to search

scientific article published on 29 July 2015

Language	Label	Description	Also known as
English	Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models.	scientific article published on 29 July 2015

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26219891%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26219891%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

based on heuristic

inferred from title

Giovanni Luca Gravina

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26219891%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26219891%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Francesco Marampon

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26219891%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Enrico Ricevuto

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26219891%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

Luca Scarsella

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26219891%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Alessandro Colapietro

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26219891%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Ana Jitariuc

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26219891%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Flora Vitale

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26219891%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Claudio Festuccia

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26219891%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

publication date

29 July 2015

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26219891%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26219891%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

37

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26219891%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26219891%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

341-351

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26219891%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3725-3

21 January 2018

Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3725-3

21 January 2018

Current indications for chemotherapy in prostate cancer patients.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3725-3

21 January 2018

Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3725-3

21 January 2018

Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3725-3

21 January 2018

Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3725-3

21 January 2018

Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3725-3

21 January 2018

The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3725-3

21 January 2018

Prostate tumorigenesis induced by PTEN deletion involves estrogen receptor β repression.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3725-3

21 January 2018

Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3725-3

21 January 2018

Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3725-3

21 January 2018

Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3725-3

21 January 2018

PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3725-3

21 January 2018

mTOR-targeted therapy of cancer with rapamycin derivatives

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3725-3

21 January 2018

Potential role of mTORC2 as a therapeutic target in clear cell carcinoma of the ovary

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3725-3

21 January 2018

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3725-3

21 January 2018

A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3725-3

21 January 2018

Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3725-3

21 January 2018

The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3725-3

21 January 2018

The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3725-3

21 January 2018

The current state of preclinical prostate cancer animal models

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3725-3

21 January 2018

Resistance to the mTOR-inhibitor RAD001 elevates integrin α2- and β1-triggered motility, migration and invasion of prostate cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3725-3

21 January 2018

Molecular characterization of human prostate carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3725-3

21 January 2018

Discrete functions of GSK3α and GSK3β isoforms in prostate tumor growth and micrometastasis

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3725-3

21 January 2018

AKT/GSK-3β regulates stability and transcription of snail which is crucial for bFGF-induced epithelial-mesenchymal transition of prostate cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3725-3

21 January 2018

Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3725-3

21 January 2018

SGK3 is an androgen-inducible kinase promoting prostate cancer cell proliferation through activation of p70 S6 kinase and up-regulation of cyclin D1.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3725-3

21 January 2018

GSK-3beta inhibition: at the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3725-3

21 January 2018

Competitive nuclear export of cyclin D1 and Hic-5 regulates anchorage dependence of cell growth and survival

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3725-3

21 January 2018

Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3725-3

21 January 2018

XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3725-3

21 January 2018

Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer models

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3725-3

21 January 2018

Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/26219891

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26219891

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term presence of androgens and anti-androgens modulate EGF-receptor expression and MAP-kinase phosphorylation in androgen receptor-prostate positive cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/26219891

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26219891

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26219891

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Akt and prostate tumorigenesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26219891

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Analysis of PTEN and the 10q23 region in primary prostate carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/26219891

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38848501&oldid=2202168939"